GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
X

XTL Biopharmaceuticals Ltd ADR XTLB · USD

Health Care · US listing · 🇺🇸 United States

Compare

1.53

-1.29%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About XTL Biopharmaceuticals Ltd ADR

Its shares trade under the ticker XTLB. It has been listed since 1 September 2005. In the fiscal year to 31 December 2024, it reported revenue of $451,000 and a net loss of $1.0m. At that date it held total assets of $8.6m and shareholders' equity of $5.4m.

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
1 Sept 2005
Employees
18
Website
xtlbio.com ↗
Head office
XTL BIOPHARMACEUTICALS LTD, NEW YORK, NY, 10016
Incorporated in
L3
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • XTL Biopharmaceuticals Ltd. has a Phase II-ready drug candidate hCDR1 for autoimmune diseases in Israel.
  • The company holds a licensing agreement with Yeda Research for hCDR1 development and commercialization.
  • XTL Biopharmaceuticals Ltd. has a 32-year history since incorporation in 1993.

Weaknesses

  • XTL Biopharmaceuticals Ltd. has only 18 employees, indicating limited operational capacity.
  • The company's business is focused solely on autoimmune disease treatments in Israel.
  • XTL Biopharmaceuticals Ltd. has no other drug candidates beyond hCDR1.

Opportunities

  • XTL Biopharmaceuticals Ltd. can expand hCDR1 to treat systemic lupus erythematosus in the US market.
  • The company may leverage its licensing agreement with Yeda Research for new indications.
  • XTL Biopharmaceuticals Ltd. could seek partnerships for global drug development.

Threats

  • XTL Biopharmaceuticals Ltd. faces competition from other biopharmaceutical companies in Israel.
  • The company's reliance on a single drug candidate hCDR1 poses significant risk.
  • XTL Biopharmaceuticals Ltd. operates in a highly regulated Health Care sector.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.